Madiha has been working on vector engineering and vaccine design for over 15 years. She has a strong background in applied molecular and cellular biotechnology, in virology and in immunology, with research interests at the interface of fundamental and translational research, the so-called bench-to-bedside. She especially focuses on immune stimulation and immune modulation, both in the oncology and infectious disease fields.

Madiha holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.

Madiha is the Scientific Founder and CEO of AMAL Therapeutics, a Swiss biotech company developing first-in-class therapeutic cancer vaccines. She designed and characterized a CPP-based multi-epitopic cancer vaccine in the Laboratory of Tumour Immunology of the University of Geneva, which is the basis of the KISIMA proprietary vaccine platform. Madiha excitingly drove the integration of AMAL Therapeutics into the Boehringer Ingelheim oncology research and development family, with the acquisition of AMAL by Boehringer Ingelheim in July 2019.

Formerly executive with Medtronic, Lysis, Sensimed, KB Medical, now with MindMaze SA. Jean-Marc has over 30 years experience in international growth management and financing. He is active since 2003 as an executive for innovative high-tech companies. Aside from various activities as a board member, coach, or financial expert, Jean-Marc spent 8 years as founder and CEO of Sensimed, then took the position of CEO with KB Medical, a company active in providing robotic assistance spinal surgery, which he led to a successful trade sale to Globus Medical. Since September 2017, Jean-Marc joined the Swiss neurotechnology unicorn MindMaze as Chief Operating Officer where he was instrumental in the company’s digital transformation, in a $230m Series B financing round with leading financial and strategic investors, and in structuring the company as an agile organization recipient of the 2022 Deloitte Best Managed Company award. Jean-Marc holds an MSc in Electrical Engineering from EPFL and an MBA from IMD.

Since co‑founding Addex in 2002, Mr. Dyer has played a pivotal role in building the Addex Group, raising significant capital, including Addex IPO and negotiating licensing agreements with pharmaceutical industry partners.

Prior to founding Addex, he spent 10 years with Price Waterhouse, or PW & PricewaterhouseCoopers, or PwC in the UK and Switzerland as part of the audit and business advisory group. At PwC in Switzerland, Mr Dyer’s responsibilities included managing the service delivery to a diverse portfolio of clients including high growth start‑up companies, international financial institutions and venture capital and investment companies.

Mr. Dyer has extensive experience in finance, corporate development, business operations and the building of start‑up companies. He is a UK Chartered Accountant and holds a BSc (Hons) in Biochemistry and Pharmacology from the University of Southampton, UK.